🔗 Permalink

Inventor profile of:

Rienk OFFRINGA

City:

Heidelberg

Country:

Germany

Published Applications:

Last publication date:

2024-11-07

Top Assignees for applications by Rienk OFFRINGA

The entities that hold a legal rights for patent applications filed by inventor OFFRINGA Rienk:

Deutsches Krebsforschungszentrum 11 Heidelberg, Germany
Bayer Aktiengesellschaft 11 Leverkusen, Germany
Bayer Pharma Aktiengesellschaft 5 Berlin, Germany
Bayer Pharma Aktiengesellschaft 1 , Germany
Bayer Aktiengesellschaft 1 , Germany
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG 1 Heidelberg, Germany
Deutsches Krebsforschungszentrum 1 , Germany
Bayer Aktiengesellschaft 1 Heidelberg, Germany

Recent patent applications by OFFRINGA Rienk

Rienk OFFRINGA from Heidelberg, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-11-07

US20240368280A1

Chemistry; metallurgy

ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS

#2 | 2024-10-03

US20240327911A1

Chemistry; metallurgy

ANTIGEN REACTIVE T-CELL RECEPTORS

#3 | 2024-05-30

US20240174683A1

Chemistry; metallurgy

MAP4K1 INHIBITORS

#4 | 2023-06-29

US20230201186A1

Human necessities

Substituted aminoquinolones as DGKalpha inhibitors for immune activation

#5 | 2023-06-01

US20230167103A1

Chemistry; metallurgy

SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION

#6 | 2023-06-01

US20230167078A1

Chemistry; metallurgy

SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION

#7 | 2023-05-11

US20230148194A1

Human necessities

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

#8 | 2023-05-04

US20230139936A1

Chemistry; metallurgy

Substituted aminothiazoles as DGKzeta inhibitors for immune activation

#9 | 2023-03-02

US20230064809A1

Human necessities

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

#10 | 2023-03-02

US20230062100A1

Human necessities

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

#11 | 2022-03-24

US20220089721A1

Chemistry; metallurgy

Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies

#12 | 2022-02-17

US20220047603A1

Human necessities

SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES

#13 | 2022-01-13

US20220010017A1

Chemistry; metallurgy

PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND EITHER ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER

#14 | 2020-08-06

US20200246347A1

Human necessities

Substituted Pyrrolopyridine-Derivatives

InventorID:

2811665 ⎘